<?xml version="1.0" encoding="UTF-8"?>
<list list-type="bullet">
 <list-item>
  <p>In blank control (BC, n = 16), mice were not infected with IAV (PR8) virus but shammed with VGM medium in a 50 μL volume intranasally, and then treated with DMSO (0.5%) by oral gavage.</p>
 </list-item>
 <list-item>
  <p>In negative control (NC, n = 16), mice were infected intranasally with 10× MLD
   <sub>50</sub> of IAV (PR8) virus in a 50 μL volume, and treated with DMSO (0.5%) by oral gavage.
  </p>
 </list-item>
 <list-item>
  <p>In positive control (PC, n = 16), mice were infected intranasally with 10× MLD
   <sub>50</sub> of IAV (PR8) virus in a 50 μL volume, and treated with oseltamivir (10 mg/kg/day) by oral gavage.
  </p>
 </list-item>
 <list-item>
  <p>In rhein-treated groups (Rhe75 and Rhe150, n = 16, respectively), mice were infected intranasally with 10× MLD
   <sub>50</sub> of IAV (PR8) virus in a 50 μL volume, and treated with rhein (75 mg/kg/day and 150 mg/kg/day, respectively) by oral gavage. The test doses are determined according to the previous reports [
   <xref rid="pone.0191793.ref024" ref-type="bibr">24</xref>–
   <xref rid="pone.0191793.ref026" ref-type="bibr">26</xref>] and our preliminary test.
  </p>
 </list-item>
</list>
